Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Nanobiotechnology ; 22(1): 174, 2024 Apr 12.
Article in English | MEDLINE | ID: mdl-38609922

ABSTRACT

Photothermal therapy is favored by cancer researchers due to its advantages such as controllable initiation, direct killing and immune promotion. However, the low enrichment efficiency of photosensitizer in tumor site and the limited effect of single use limits the further development of photothermal therapy. Herein, a photo-responsive multifunctional nanosystem was designed for cancer therapy, in which myeloid-derived suppressor cell (MDSC) membrane vesicle encapsulated decitabine-loaded black phosphorous (BP) nanosheets (BP@ Decitabine @MDSCs, named BDM). The BDM demonstrated excellent biosafety and biochemical characteristics, providing a suitable microenvironment for cancer cell killing. First, the BDM achieves the ability to be highly enriched at tumor sites by inheriting the ability of MDSCs to actively target tumor microenvironment. And then, BP nanosheets achieves hyperthermia and induces mitochondrial damage by its photothermal and photodynamic properties, which enhancing anti-tumor immunity mediated by immunogenic cell death (ICD). Meanwhile, intra-tumoral release of decitabine induced G2/M cell cycle arrest, further promoting tumor cell apoptosis. In vivo, the BMD showed significant inhibition of tumor growth with down-regulation of PCNA expression and increased expression of high mobility group B1 (HMGB1), calreticulin (CRT) and caspase 3. Flow cytometry revealed significantly decreased infiltration of MDSCs and M2-macrophages along with an increased proportion of CD4+, CD8+ T cells as well as CD103+ DCs, suggesting a potentiated anti-tumor immune response. In summary, BDM realizes photothermal therapy/photodynamic therapy synergized chemotherapy for cancer.


Subject(s)
Myeloid-Derived Suppressor Cells , Neoplasms , Photochemotherapy , Biomimetics , CD8-Positive T-Lymphocytes , Decitabine/pharmacology , Photothermal Therapy , Neoplasms/drug therapy
2.
Adv Healthc Mater ; 13(13): e2400068, 2024 May.
Article in English | MEDLINE | ID: mdl-38320299

ABSTRACT

Cancer nanovaccines have attracted widespread attention by inducing potent cytotoxic T cell responses to improve immune checkpoint blockade (ICB) therapy, while the lack of co-stimulatory molecules limits their clinical applications. Here, a genetically engineered cancer cytomembrane nanovaccine is reported that simultaneously overexpresses co-stimulatory molecule CD40L and immune checkpoint inhibitor PD1 to elicit robust antitumor immunity for cancer immunotherapy. The CD40L and tumor antigens inherited from cancer cytomembranes effectively stimulate dendritic cell (DC)-mediated immune activation of cytotoxic T cells, while the PD1 on cancer cytomembranes significantly blocks PD1/PD-L1 signaling pathway, synergistically stimulating antitumor immune responses. Benefiting from the targeting ability of cancer cytomembranes, this nanovaccines formula shows an enhanced lymph node trafficking and retention. Compared with original cancer cytomembranes, this genetically engineered nanovaccine induces twofold DC maturation and shows satisfactory precaution efficacy in a breast tumor mouse model. This genetically engineered cytomembrane nanovaccine offers a simple, safe, and robust strategy by incorporating cytomembrane components and co-stimulatory molecules for enhanced cancer immunotherapy.


Subject(s)
Cancer Vaccines , Dendritic Cells , Immunotherapy , Animals , Immunotherapy/methods , Mice , Cancer Vaccines/immunology , Dendritic Cells/immunology , Female , Humans , Programmed Cell Death 1 Receptor/immunology , Programmed Cell Death 1 Receptor/metabolism , Cell Line, Tumor , Antigens, Neoplasm/immunology , Antigens, Neoplasm/genetics , Genetic Engineering/methods , Nanoparticles/chemistry , Mice, Inbred BALB C , T-Lymphocytes, Cytotoxic/immunology , B7-H1 Antigen/metabolism , B7-H1 Antigen/immunology , Neoplasms/therapy , Neoplasms/immunology , Nanovaccines
3.
Anal Sci ; 20(12): 1697-700, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15636518

ABSTRACT

Trace amounts of Be (0.046-2.59 ng) in a dried marine organism sample (10 mg) could be accurately determined by GFAAS after treating with microwave digestion (HNO3/H2O2) at 85 degrees C for 10 min and using acetylacetone as a chelating agent in the presence of an acetate buffer (pH 6.0). The method detection limit (MDL, 3sigma) for Be was found to be 4.6 ng g(-1); the calibration graph was linear up to 259 ng g(-1). Good recoveries (98.5-105.0%) were obtained for eight marine organism samples (including five fish, one lobster, one oyster, and one algae) with a relative standard deviation (RSD, n = 3) < 3.0%. The proposed method could be applied measurements of Be in various marine organisms.


Subject(s)
Beryllium/analysis , Marine Biology , Pentanones/chemistry , Animals , Chelating Agents/chemistry , Eukaryota , Fishes , Ostreidae , Palinuridae , Reproducibility of Results , Sensitivity and Specificity , Spectrophotometry, Atomic/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...